Concepedia

CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts

Lucie Laurent, David Sefrioui, Anne-Laure Bignon, Aurélie Parzy, Sabrina Sidali, Mélanie Hassine, Alice Gangloff, Marie‐Pierre Galais, Karine Bouhier‐Leporrier, Pierre Michel,

HPB · 2018 · 19 citations · 22 references

DOIFull text

Open access

Concepts

References

22

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Umashankar K. Ballehaninna, Ronald S. Chamberlain · PubMed · 2012 · 700 citations · Full text

, , +17

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Margaret A. Tempero, E. Uchida, Hideaki Takasaki et al. · PubMed · 1987 · 402 citations

, , +17

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker

Daniel Pietrasz, Nicolas Pécuchet, Fanny Garlan et al. · Clinical Cancer Research · 2016 · 267 citations · Full text

, , +17

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

Viviane Hess, Bengt Glimelius, Philipp Grawe et al. · The Lancet Oncology · 2008 · 238 citations

, , +5